FOI Request
- Disclosure ID
- FOI/03323
- Request Date
- September 16, 2019
- Subject
- Renal Cell Carcinoma Patients
- Description
1). In the past 12 months, how many metastatic Renal Cell Carcinoma patients were treated with:
Sunitinib
Pazopanib
Everolimus
Temsirolimus
Cabozantinib
Nivolumab
Axinitib
Nivolumab + Ipilimumab
Lenvantinib + Everolimus
Tivozanib
Pembrolizumab + Axitinib
Avelumab + Axitinib
2). In the past 12 months, how many metastatic Hepatic Cell Carcinoma patients were treated with:
Bevacizumab
Cisplatin
Doxorubicin
Everolimus
Lapatinib
Lenvantinib
Regorafenib
Sorafenib
Sunitinib
- Response
1). We do not record this information in an easily accessible format; to retrieve it would require a manual trawl of patient case notes which would exceed 18 hours. This information is therefore exempt on the grounds of cost (Section 12(1)).
2). We do not record this information in an easily accessible format; to retrieve it would require a manual trawl of patient case notes which would exceed 18 hours. This information is therefore exempt on the grounds of cost (Section 12(1)).
Please see attached further response